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Abstract
Introduction
Recent studies indicate an increased risk of colorectal can-
cer in people with diabetes. However, people with diabetes 
may  have  lower  colorectal  cancer  screening  rates  than 
people without diabetes. Few data are available regarding 
factors associated with lack of screening for people with 
diabetes. Our objective was to describe factors associated 
with lack of timely colorectal cancer screening in people 
with diabetes.
Methods
We examined an electronic medical record database with 
more  than  6,000  patients  aged  50  years  or  older  who 
had diabetes and were seen in a large hospital system in 
Boston, Massachusetts. We compared patients who had 
received timely colorectal cancer screening with those who 
had not on several variables, including glycemic control, 
expressed as average hemoglobin A1c (HbA1c). Bivariate 
analyses were performed using χ2 and t tests for means 
when applicable. Logistic regression was used to deter-
mine the independent association of variables with lack 
of screening.
Results
Patients  with  poor  glycemic  control  (average  HbA1c 
>8.5%)  were  more  likely  not  to  have  been  screened  for 
colorectal cancer than those with good glycemic control, 
even after adjusting for the number of primary care visits. 
Patients with fewer than 20 primary care visits in 5 years 
were more likely not to have been screened than those 
with more visits.
Conclusion
Glycemic control appears to be independently associated 
with the likelihood of colorectal cancer screening. People 
with  poorly  controlled  diabetes  should  be  targeted  in 
future research and individual patient care.
Introduction
Researchers  have  noted  an  increased  risk  of  colorectal 
cancer and its precursors in people with diabetes (1-5). 
This  increased  risk  is  hypothesized  to  be  secondary  to 
several factors, such as increased circulating insulin and 
insulin-like growth factor (IGF-1), and to effects of treat-
ment for diabetes (6-8). Awareness of this increased risk 
may encourage health care providers to promote colorectal 
cancer screening to patients with diabetes. Primary care 
physicians are the most likely candidates to recommend 
screening, since they provide care to the majority of dia-
betes patients nationally (9-11) and are primarily respon-
sible for screening and prevention.
Rates of colorectal cancer screening in many states were 
below 50% between 1998 and 2005 (12), although more 
recent data indicate rates of 50% to 60% in most states 
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and 60% to 70% in others (13). The US Preventive Services 
Task Force recommends colonoscopy every 10 years, sig-
moidoscopy  every  5  years,  or  annual  fecal  occult  blood 
testing (FOBT) starting at age 50 and continuing until at 
least age 75 (14). Efforts are under way to increase rates of 
colorectal cancer screening among racial/ethnic minorities 
but have not targeted people with diabetes, even though 
their risk for colorectal cancer may be higher than the 
risk for the general population (15). People with diabetes 
may be less likely to pursue any cancer screening (16,17), 
even with more primary care visits per year than patients 
without diabetes (18).
Glycemic control may be associated with colorectal cancer 
screening in people with diabetes for several reasons. Many 
diabetic patients with good glycemic control (hemoglobin 
A1c  [HbA1c]  <7.0%)  visit  their  physician  regularly  and 
adhere to lifestyle recommendations regarding diabetes; 
therefore, they would have more frequent opportunities 
to hear about screening and may be more likely to accept 
colorectal cancer screening recommendations. People with 
fair (HbA1c 7.0%-8.5%) or poor (HbA1c >8.5%) glycemic 
control may visit their physician less regularly and be less 
likely to adhere to prescribed dietary and medication regi-
mens, and may be less likely to accept colorectal cancer 
screening recommendations.
However, even when receiving regular care, patients with 
poorly controlled diabetes may not be screened for colorec-
tal  cancer.  They  may  have  multiple  medical  and  social 
issues for the physician to address at each visit, and a sub-
stantial amount of the visit may be devoted to improving 
glycemic control, leaving the physician unable to accom-
plish all preventive goals (19). These patients may also be 
more medically complex, with more diabetic complications, 
leading the physician to defer colorectal cancer screening 
until they are more stable.
The existing research on low rates of screening for other 
cancers in people with diabetes and on competing priori-
ties in the office visit prompted us to examine associations 
between  glycemic  control  and  rates  of  colorectal  cancer 
screening  in  people  with  diabetes.  The  objective  of  this 
study was to examine the association between glycemic 
control (average HbA1c) and colorectal cancer screening 
rates  (colonoscopy  or  sigmoidoscopy  within  5  years  or 
FOBT within 1 year) in a large urban hospital with robust 
numbers  of  racial/ethnic  minorities  and  large  numbers 
of patients with poorly controlled diabetes. The findings 
from this study should add to physician awareness about 
colorectal  cancer  screening  for  people  with  diabetes  by 
identifying  their  unique  factors  associated  with  lack  of 
screening and generate hypotheses for future research.
Methods
Database
We conducted a secondary data analysis by using a large 
database  that  contained  elements  of  de-identified  elec-
tronic  medical  records  at  a  large  safety-net  hospital  in 
Boston, Massachusetts (historically, >80% of patients have 
had some form of government insurance, and >50% of the 
patient  population  comprises  racial/ethnic  minorities). 
Patients were included in the analysis if they were listed 
as having a diagnosis of diabetes, were aged 50 years or 
older on January 1, 2005, had a primary care physician 
at the hospital, and had at least 1 HbA1c value listed in 
the database between January 1, 2005, and January 1, 
2010 (n = 6,066). Any patients who met these criteria were 
included, regardless of the number of HbA1c values chart-
ed or the number of primary care visits. Patients were 
excluded if they had a diagnosis of colorectal cancer. This 
project was designated as “exempt” by the institutional 
review  board  at  Boston  University  School  of  Medicine/
Boston Medical Center.
Most patients at this institution receive both their primary 
care and any procedural services (eg, colonoscopy or sig-
moidoscopy) at the institution for insurance reasons, so we 
were confident, based on prior analyses of this database, 
that nearly all episodes of screening would be captured.
Variables
The dependent variable, colorectal cancer screening, was 
defined  as  having  a  documented  episode  of  either  colo-
noscopy or sigmoidoscopy between January 1, 2005, and 
January 1, 2010, or FOBT between January 1, 2009, and 
January 1, 2010 (the data were assembled in May 2010). 
We  also  conducted  sensitivity  analyses  with  10-year 
screening rates of colonoscopy for patients who were aged 
50 years or older on January 1, 2000. We chose the 5-year 
rather than the 10-year screening variable for our primary 
analyses because we felt that other variables of interest, 
notably HbA1c and number of primary care visits, would 
be less consistent over a longer time period. The indepen-
dent variable of interest, glycemic control, was defined as 
the average HbA1c between January 1, 2005, and January VOLUME 8: NO. 4
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1, 2010. For the bivariate analyses, we defined good con-
trol as HbA1c less than or equal to 7.0%, fair as HbA1c 
7.0% to 8.5%, and poor as HbA1c greater than 8.5%. For 
the logistic regression, these categories were collapsed into 
good (≤8.5%) and poor (>8.5%).
Several covariates were also analyzed: age (continuous), 
sex,  race/ethnicity  (patients  self-identify  at  registration 
and  we  collapsed  the  many  subcategories  into  white, 
black, Latino, or other to be consistent with other studies), 
language preference (English or non-English, indicated by 
the patient during registration), and number of primary 
care visits in 5 years (assuming the ideal is 4 visits per 
year  for  diabetic  patients,  we  categorized  the  number 
of visits as low [<20], ideal [20-30], and high [>30]). We 
also examined insurance status at the beginning of the 
5-year period (government insurance, private insurance, 
or  no  insurance);  emergency  department  (ED)  visits  in 
the 5-year period (<10, 10-20, and >20); no-shows for clini-
cal appointments in the 5-year period (continuous); and 
incidence of end-stage renal disease (yes or no), which can 
complicate preparations for colorectal cancer screening.
Statistical analysis
We performed bivariate analyses using χ2 tests to deter-
mine which variables were associated with lack of screening 
and with good, fair, and poor HbA1c averages. Correlation 
coefficients were used to confirm the relationship between 
primary  care  visits,  ED  visits,  and  no-shows.  Finally, 
logistic regression was employed to determine the inde-
pendent association of variables of interest with colorectal 
cancer screening. We selected our model by sequentially 
removing variables from the model and leaving them out 
if their removal did not change any odds ratios by 10% 
or more. We wanted to show any potentially interesting 
associations, but our large database could result in some 
associations  being  statistically  significant  but  clinically 
insignificant. Consequently, the final model contains only 
variables  that  1)  were  significant  in  the  initial  model 
with respect to colorectal cancer screening and 2) when 
removed from the model, changed other associations by 
10% or more. SAS version 9.1 (SAS Institute, Inc, Cary, 
North Carolina) was used for all analyses.
Results
The  study  population  was  58%  female,  57%  black,  and 
14% Latino (Table 1). The colorectal cancer screening rate 
overall  was  38%.  Most  patients  (59%)  were  covered  by 
some form of government insurance; 22% had no listed 
insurance  and  19%  had  private  insurance.  Thirty-six 
percent of patients had good glycemic control, 37% fair 
control, and 27% poor control.
Average HbA1c was strongly associated with screening; 
the highest rates of screening occurred in patients whose 
HbA1c was 8.5% or less (Table 1). We observed significant 
associations  for  race/ethnicity;  patients  with  end-stage 
renal disease also had higher screening rates than those 
without.  Higher  numbers  of  primary  care  visits  were 
strongly associated with screening, as expected. However, 
more frequent ED visits also appeared to be strongly asso-
ciated with screening.
On  average,  patients  with  poor  (>8.5%)  HbA1c  values 
tended  to  be  younger,  uninsured,  nonwhite,  and  have 
higher rates of no-shows compared with patients exhibit-
ing good and fair HbA1c values (Table 2). The number of 
primary care visits did not appear to be lower in the group 
with high HbA1c values.
Correlation coefficients indicated that primary care visits 
were weakly correlated with ED visits (ρ = 0.19) and no-
shows  (ρ  =  0.34).  Although  the  Pearson  and  Spearman 
coefficients  were  similar,  we  report  the  Spearman  coef-
ficients because the numbers of primary care visits, ED 
visits, and no-shows were not normally distributed.
We also performed sensitivity analyses to examine differ-
ent  types  of  colorectal  cancer  screening  individually  by 
HbA1c level. We found that for all screening groups (5-
year colonoscopy, 5-year sigmoidoscopy, 1-year FOBT, and 
10-year colonoscopy) the rates of colorectal cancer screen-
ing decreased as the glycemic control worsened.
In the final logistic regression model, poor average HbA1c 
was predictive of not receiving colorectal cancer screen-
ing, as was having had fewer than 20 primary care visits 
in a 5-year period (Table 3). Patients with either govern-
ment or private insurance were more likely to have been 
screened than those with no insurance.
Discussion
Poor  glycemic  control  was  associated  with  not  being 
screened  for  colorectal  cancer,  even  after  adjusting  for 
number of primary care visits and for insurance status. VOLUME 8: NO. 4
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This  finding  suggests  that  the  issue  for  these  patients 
goes beyond simply not being seen in primary care offices; 
there may also be issues of competing priorities (19,20) in 
the office visit when they do go. Either physicians occupied 
with helping their patients to gain better glycemic control 
may be less likely to recommend colorectal cancer screen-
ing, or patients struggling to gain better glycemic control 
may be less likely to follow through on the recommenda-
tion. Other studies on cancer screening in people with dia-
betes (16-18) have also noted lower rates of screening and 
proposed similar hypotheses (both patient and physician 
factors)  for  them.  Further  research,  with  primary  data 
collection, would be ideal to define barriers to colorectal 
cancer screening specifically for people with diabetes.
The emerging research on colorectal cancer risk for people 
with  diabetes  suggests  that  diabetic  patients  with  poor 
glycemic control may have even higher risk because they 
exhibit high levels of circulating insulin and IGF-1 and 
are often receiving multiple treatments (21-25). Therefore, 
people with poorly controlled diabetes are an important 
group to target for colorectal cancer screening, even if the 
care providers are spending most of their time on diabetes 
management.
This  study  had  several  limitations.  Although  the  data-
base’s information was extracted from electronic medical 
records and was complete for most variables, we could not 
obtain reliable data on several variables of interest: years 
since diabetes diagnosis, type of diabetes, other diabetic 
complications beyond end-stage renal disease, reason for 
colonoscopy (screening vs diagnostic), and physician rec-
ommendation for colorectal cancer screening. These are all 
variables that should be examined further for associations 
with colorectal cancer screening among people with dia-
betes. The data also came from a large, urban, safety-net 
hospital with large numbers of black and Latino patients. 
We  considered  this  a  strength  in  terms  of  obtaining  a 
robust sample of racial/ethnic minorities for analyses, but 
the association of both groups with higher colorectal can-
cer screening rates (compared with white patients) may 
not be generalizable to other settings.
We hope the findings of this study will help to provide 
context for the recent studies associating diabetes with a 
higher risk of colorectal cancer and polyps; this informa-
tion is more valuable if more is known about the colorectal 
cancer screening patterns of people with diabetes and the 
specific factors associated with lack of colorectal cancer 
screening for this group. Further studies are needed to 
explore this finding and to determine the association of 
other variables with colorectal cancer screening for people 
with diabetes. Future research could specifically examine 
variables related to the hypotheses we generated about 
low colorectal cancer screening rates in people with poor 
glycemic control but adequate numbers of primary care 
visits, to define whether patient factors or physician fac-
tors are more closely related to the lack of colorectal cancer 
screening. This information might help health care sys-
tems to promote screening in this group of patients, which 
appears to be more at risk for colorectal cancer and more 
at risk for not being screened.
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Tables
Table 1. Associations of Health Care Use and Demographic and Health Characteristics With Receiving Colorectal Cancer Screeninga, 
Boston, Massachusetts, 2005-2010b
Characteristic n
% Who Had Colorectal Cancer 
Screening
% With No Colorectal Cancer 
Screening P Valuec
Age, mean (SD), y 6,066 62. (8.6) 64. (9.6) <.001d
Sex
Male 2,62 8.7 61.
.4
Female ,04 7.7 62.
Race/ethnicity
White 984 7. 62.
<.001
Black ,46 9.0 61.0
Latino 8 8.8 61.2
Other 791 4.8 6.2
Language preference
English 4,198 9.7 60.
.4
Other 1,868 4.6 6.4
End-stage renal disease
Yes 40 46. .
<.001
No ,66 7. 62.
No. of ED visits in 5 years
<10 ,84 8.6 61.4
<.001
10-20 68 0.7 49.
>20 19 9.1 40.9
None/no data available 1,460 29.4 70.6
Mean no. of no-shows for 5-year period (SD) 9,109 9.0 (9.2) 7.1 (7.6) <.001d
Health insurance coverage
Government ,79 40.4 9.6
<.001 Private 1,16 4.0 7.0
None 1,1 28.0 72.0
 
Abbreviations: SD, standard deviation; ED, emergency department; HbA1c, hemoglobin A1c. 
a Defined as colonoscopy or sigmoidoscopy within  years or fecal occult blood test within 1 year. 
b All patients in sample were aged ≥50 y and had been diagnosed with diabetes. Values are percentages unless otherwise indicated. 
c Calculated by using χ2 tests, except where indicated by footnote d. 
d Calculated by using independent t tests. 
e Total for this variable is not 6,066 because of missing values.
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Characteristic n
% Who Had Colorectal Cancer 
Screening
% With No Colorectal Cancer 
Screening P Valuec
No. of primary care visits in 5 years
>0 2 61.1 8.9
<.001
20-0 1,287 49.4 0.6
1-19 ,722 2.4 67.6
0 2 27.8 72.2
Mean no. of HbA1c tests (SD) 9,09 8.4 (4.4) .9 (4.) <.001d
Mean HbA1c, %e
<7.0 2,184 40. 9.7
<.001 7.0-8. 2,267 41.1 8.9
>8. 1,60 1.2 68.8
 
Abbreviations: SD, standard deviation; ED, emergency department; HbA1c, hemoglobin A1c. 
a Defined as colonoscopy or sigmoidoscopy within  years or fecal occult blood test within 1 year. 
b All patients in sample were aged ≥50 y and had been diagnosed with diabetes. Values are percentages unless otherwise indicated. 
c Calculated by using χ2 tests, except where indicated by footnote d. 
d Calculated by using independent t tests. 
e Total for this variable is not 6,066 because of missing values.
Table 2. Associations of Health Care Use and Demographic and Health Characteristics With Glycemic Control, Boston, 
Massachusetts, 2005-2010a
Characteristic n Mean HbA1c <7.0%
Mean HbA1c 7.0%-
8.5% Mean HbA1c >8.5% P Valueb
Age, mean (SD), y 6,066 6.2 (10.0) 6.7 (9.1) 61. (8.) <.001c
Sex
Male 2,62 . 7.0 27.
.7
Female ,04 6.4 7.7 2.8
Race/ethnicity
White 984 47.1 6.4 16.6
<.001
Black ,46 4.1 7.4 28.2
Latino 8 . 6.8 29.8
Other 791 .4 9.2 27.4
 
Abbreviations: HbA1c, hemoglobin A1c; SD, standard deviation; ED, emergency department. 
a All patients in sample were aged ≥50 y and had been diagnosed with diabetes. Values are percentages unless otherwise indicated. 
b Calculated by using χ2 tests, except where indicated by footnote c. 
c Calculated by using the F statistic with generalized linear models.
Table 1. (continued) Associations of Health Care Use and Demographic and Health Characteristics With Receiving Colorectal Cancer 
Screeninga, Boston, Massachusetts, 2005-2010b
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Characteristic n Mean HbA1c <7.0%
Mean HbA1c 7.0%-
8.5% Mean HbA1c >8.5% P Valueb
Language preference
English 4,198 8.7 6.6 24.6
<.001
Other 1,868 29.9 9.2 0.7
End-stage renal disease
Yes 40 9. 7.7 22.8
.19
No ,66 .7 7.4 26.7
No. of ED visits in 5 years
<10 ,84 4.8 7.6 27.4
<.001
10-20 68 7.7 4.0 28.4
>20 19 7.8 7.8 24.4
None/no data available 1,460 8.2 8.2 2.6
Mean no. of no-shows for 5-year period (SD) 9,109 6. (7.4) 7.2 (7.4) 9. (9.7) <.001c
Health insurance coverage
Government ,79 7.2 8.1 24.6
<.001 Private 1,16 8. .9 2.6
None 1,1 0.8 6.7 2.2
No. of primary care visits in 5 years
>0 2 1.4 41.2 27.4
<.001
20-0 1,287 .0 4. 21.
1-19 ,722 .6 .4 28.8
0 2 4.9 2.8 21.
Mean no. of HbA1c tests (SD) 9,09 6.1 (4.) 7.6 (4.6) 6.9 (4.9) <.001c
 
Abbreviations: HbA1c, hemoglobin A1c; SD, standard deviation; ED, emergency department. 
a All patients in sample were aged ≥50 y and had been diagnosed with diabetes. Values are percentages unless otherwise indicated. 
b Calculated by using χ2 tests, except where indicated by footnote c. 
c Calculated by using the F statistic with generalized linear models.
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Table 3. Odds of Not Receiving Colorectal Cancer Screeninga, by Health Care Use and by Demographic and Health Characteristics, 
Boston, Massachusetts, 2005-2010b
Characteristic OR (95% CI) Adjusted OR (95% CI)
Glycemic control
HbA1c >8.% 1.1 (1.4-1.71) 1.6 (1.8-1.77)
HbA1c ≤8.5% 1 [Reference]
Sex
Male 1 [Reference]
Female 1.04 (0.94-1.16) NC
Race/ethnicity
White 1 [Reference]
Black 0.92 (0.8-1.0) NC
Latino 0.97 (0.8-1.1) NC
No. of primary care visits in 5 years
≥20 1 [Reference]
<20 2.40 (2.14-2.68) 2.19 (1.9-2.46)
No. of ED visits in 5 years
0-10 1 [Reference]
>10 1.0 (0.94-1.17) NC
Age, yc 1.02 (1.02-1.0) 1.0 (1.02-1.0)
End-stage renal disease
Yes 0.69 (0.7-0.84) NC
No 1 [Reference]
Language preference
English 1 [Reference]
Other 1.2 (1.11-1.40) NC
Health insurance coverage
Government 0.79 (0.71-0.88) 0.70 (0.60-0.80)
Private 0.78 (0.68-0.89) 0.68 (0.7-0.81)
None 1 [Reference]
 
Abbreviations: OR, odds ratio; CI, confidence interval; HbA1c, hemoglobin A1c; NC, not calculated; ED, emergency department. 
a Defined as colonoscopy or sigmoidoscopy within  years or fecal occult blood test within 1 year. 
b All patients in sample were aged ≥50 y and had been diagnosed with diabetes. 
c Any selected age (≥50 y) can be used as the reference group. For example, to estimate the odds of not receiving colorectal cancer screening among people 
aged 70 y with people aged 0 y, subtract 0 from 70 and raise the OR (1.02) or adjusted OR (1.0) to that power.